Genprex (GNPX) Cash & Equivalents (2016 - 2026)

Genprex's Cash & Equivalents history runs 11 years deep, the most recent figure standing at $18.0 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 420.4% year-over-year to $18.0 million; the TTM figure through Mar 2026 stood at $18.0 million (up 420.4% YoY), while the FY2025 annual figure was $7.8 million, up 388.92% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $18.0 million, up from $7.8 million in the prior quarter.
• The five-year high for Cash & Equivalents was $34.6 million in Q1 2022, with the low at $1.1 million in Q3 2025.
• The 5-year median for Cash & Equivalents is $8.2 million (2024), against an average of $11.9 million.
• The sharpest annual moves came in 2024 and 2026: Cash & Equivalents tumbled 87.29% in 2024, then soared 420.4% in 2026.
• Genprex's Cash & Equivalents stood at $21.0 million in 2022, then tumbled by 67.85% to $6.7 million in 2023, then plunged by 76.23% to $1.6 million in 2024, then soared by 388.92% to $7.8 million in 2025, then soared by 130.49% to $18.0 million in 2026.
• Business Quant data shows GNPX's Cash & Equivalents at $18.0 million in Q1 2026, $7.8 million in Q4 2025, and $1.1 million in Q3 2025.